Get the Stockscreener App
0.7362
0.99%
0.0072
Mink Therapeutics Inc stock is traded at $0.7362, with a volume of 13,346.
It is up +0.99% in the last 24 hours and up +2.66% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.
See More
Previous Close:
$0.729
Open:
$0.749
24h Volume:
13,346
Relative Volume:
0.39
Market Cap:
$29.26M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-0.9561
EPS:
-0.77
Net Cash Flow:
$-17.36M
1W Performance:
+0.85%
1M Performance:
+2.66%
6M Performance:
-24.88%
1Y Performance:
-37.08%
1-Day Range:
$0.73
$0.749
1-Week Range:
$0.6765
$0.75
52-Week Range:
$0.57
$1.90
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Mink Therapeutics Inc Stock (INKT) Latest News
AGENAgenus Inc. Latest Stock News & Market Updates - StockTitan
Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update - Business Wire
MiNK Therapeutics Appoints Dr. Robert Kadlec to Board - TipRanks
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 - The Manila Times
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors - GlobeNewswire
Small Cell Lung Cancer Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
BBerg Commodity Index (AHH20) Quote - The Globe and Mail
TSX Industrials Capped Index (TTIN) QuotePress Release - The Globe and Mail
Altria Group (MO-N) QuotePress Release - The Globe and Mail
TSX 60 Equal Weight Index (TXEW) QuotePress Release - The Globe and Mail
TSX Energy Capped Index (TTEN) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Realty Income Corp (O-N) QuotePress Release - The Globe and Mail
TSX Global Base Metals Index (TXBM) QuotePress Release - The Globe and Mail
Nasdaq Biotechnology Index (NBI) QuotePress Release - The Globe and Mail
Alphabet Cl C (GOOG-Q) QuotePress Release - The Globe and Mail
Refractory Multiple Myeloma Pipeline Therapeutics, - openPR
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
S&P 500 Information Technology [Sector] (SRIT) QuotePress Release - The Globe and Mail
Meta Platforms Inc (META-Q) QuotePress Release - The Globe and Mail
CAR-T Cell Therapy Competitive Landscape 2024 (Updated) - openPR
MiNK Therapeutics announces executive transition By Investing.com - Investing.com Australia
MiNK Therapeutics announces executive transition - Investing.com India
Renaissance Technologies LLC Invests $117,000 in Generation Income Properties, Inc. (NASDAQ:GIPR) - Defense World
Rx Rundown: AstraZeneca, Danco Laboratories, GSK and more - MM+M Online
Poseida Therapeutics’ Allogeneic CAR-T P-BCMA-ALLO1 Demonstrates 91% ORR in Enhanced Lymphodepletion Arm of R/R MM Study - CGTLive™
MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
MiNK Therapeutics stock gets boost from new RNA collaboration with Autonomous - Investing.com Canada
Mink Therapeutics and Autonomous Therapeutics target metastatic tumors through new collaboration - BioWorld Online
Investor’s Toolkit: Key Ratios for Assessing MiNK Therapeutics Inc (INKT)’s Performance - The Dwinnex
MiNK Therapeutics, Autonomous Therapeutics enter research collaboration - TipRanks
ZenaTech's ZenaDrone Commences Aerial Operations to Commercialize Drone Services in the US Following FAA Approval - The Manila Times
MiNK Therapeutics and Autonomous Therapeutics Announce - GlobeNewswire
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors - Yahoo Finance
Mink Therapeutics stock hits 52-week low at $0.71 amid market challenges - Investing.com
Mink Therapeutics stock hits 52-week low at $0.71 amid market challenges By Investing.com - Investing.com South Africa
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - The Manila Times
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024 - The Bakersfield Californian
Voyageur Mineral Explorers Corp. Options Mink Narrows Project - Yahoo Finance
Oatly Group (NASDAQ:OTLY) Trading Down 4.9% - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Position Boosted by Northeast Financial Consultants Inc - Defense World
KeyCorp Raises Xcel Energy (NASDAQ:XEL) Price Target to $69.00 - Defense World
BlackRock Short Duration Bond ETF (BATS:NEAR) Sets New 52-Week High at $51.31 - Defense World
Creative Planning Purchases 14,858 Shares of Novartis AG (NYSE:NVS) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Cubist Systematic Strategies LLC - Defense World
Twin Lakes Capital Management LLC Sells 125 Shares of The Boeing Company (NYSE:BA) - Defense World
Invst LLC Raises Stock Holdings in Phillips 66 (NYSE:PSX) - Defense World
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):